Fosamprenavir in Infants and Children with HIV-1 Infection

109 34
Fosamprenavir in Infants and Children with HIV-1 Infection

Abstract and Introduction

Introduction


on April 27, 2012, the Food and Drug Administration (FDA) announced the extension of approval for fosamprenavir to include patients 4 weeks of age and older with HIV-1 infection. Fosamprenavir was approved by the FDA for use in adults on October 20, 2003 and has become a common part of highly active antiretroviral treatment (HAART) regimens. Approval was extended to children over 6 years of age in October 2007. With the availability of new clinical research resulting in the extension of approval to infants and young children, fosamprenavir is now an option for more patients with HIV-1 infection.

Subscribe to our newsletter
Sign up here to get the latest news, updates and special offers delivered directly to your inbox.
You can unsubscribe at any time

Leave A Reply

Your email address will not be published.